Clinical Pharmacokinetics

, Volume 25, Issue 1, pp 1–5 | Cite as

Dose Response Evaluation

Use of Plasma Concentration Confidence Intervals as a Tool to Predict Optimal Drug Dose Ratio
  • Per Eystein Lønning
Leading Article


This paper suggests that pharmacokinetic data might provide a rational basis to improve dose-response trials. Construction of plasma concentration confidence intervals may be a tool to predict optimal drug dose ratios for dose-response studies and, for some drugs, may point to the need for plasma concentration measurement in clinical practice. An important task now is to integrate pharmacokinetic knowledge into the design of clinical trials. To facilitate this, studies on clinical pharmacokinetics should report individual plasma AUC or clearance values or give the 95% confidence intervals of the observation.


Advanced Breast Cancer Plasma Drug Concentration Medroxyprogesterone Acetate Aminoglutethimide Sponse Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bonneterre J, Coppens H, Mauriac L, Metz M, Rousse J, et al. Aminoglutethimide in advanced breast cancer. Clinical results of a French multicenter randomized trial comparing 500mg and 1g per day. European Journal of Cancer and Clinical Oncology 21: 1153–1158, 1985CrossRefGoogle Scholar
  2. Bruning PF, Bonfrer JMG, Hart AAM, van der Linden E, de Jong-Bakker M, et al. Low dose aminoglutethimide without hydro-cortisone for the treatment of advanced postmenopausal breast cancer. European Journal of Cancer and Clinical Oncology 25: 369–376, 1989CrossRefGoogle Scholar
  3. Gallagher CJ, Cairnduff F, Smith IE. High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer. European Journal of Cancer and Clinical Oncology 23: 1895–1900, 1987CrossRefGoogle Scholar
  4. Glantz SA. Primer of biostatistics, 2nd ed., McGraw-Hill Book Company, New York, 1987Google Scholar
  5. Hodges JL, Lehmann EL. Basic concepts of probability and statistics, Holden Day Inc., San Francisco, 1970Google Scholar
  6. Johnson RA, Wichern DW. Applied multivariate analysis, Prentice-Hall Inc., Englewood Cliffs, NJ, 1982Google Scholar
  7. Lindgren BW. Statistical theory, MacMillan Company, London, 1962Google Scholar
  8. Lønning PE. Aromatse inhibition: past, present and future. In Dousett M (Ed.) Endocrine aspects of breast cancer, pp. 53–75, Parthenon Publishing Group, Carnforth, 1992Google Scholar
  9. Lønning PE, Schanche JS, Kvinnsland S, Ueland PM. Single-dose and steady-state pharmacokinetics of aminoglutethimide. Clinical Pharmacokinetics 10: 353–364, 1985PubMedCrossRefGoogle Scholar
  10. Newell DR. Phase I clinical studies with cytotoxic drugs: pharmacokinetic and pharmacodynamic considerations. British Journal of Cancer 61: 189–191, 1990PubMedCrossRefGoogle Scholar
  11. Robustelli della Cuna G. 500mg versus 1000mg aminoglutethimide (AG) in advanced breast cancer: 3 years results of an Italian multicentre trial. European Journal of Cancer 27 (Suppl. 2): s69, 1991Google Scholar
  12. Rosner B. Fundamentals of biostatistics, Duxbury Press, Boston, 1982Google Scholar
  13. Simon RM. Design and conduct of clinical trials. In DeVita Jr VT et al. (Eds) Cancer — principles and practice of oncology, pp. 329–350, J.B. Lippincott Company, Philadelphia, 1985Google Scholar
  14. Spiegel MR. Probability and statistics, McGraw-Hill Book Company, New York, 1975Google Scholar
  15. Strocchi E, Camaggi CM, Martoni A, Cellerino R, Miseria S, et al. Aminoglutethimide in advanced breast cancer: plasma levels and clinical results after low and high doses. Cancer Chemotherapy and Pharmacology 27: 451–455, 1991PubMedCrossRefGoogle Scholar
  16. van Veelen H, Wilemse PHB, Sleijfer DT, Sluiter WJ, Doorenbos H. Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer. Cancer Treatment Reports 69: 977–983, 1985PubMedGoogle Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • Per Eystein Lønning
    • 1
    • 2
  1. 1.Department of OncologyHaukeland University HospitalBergenNorway
  2. 2.University of BergenBergenNorway

Personalised recommendations